Browse > Article
http://dx.doi.org/10.5808/GI.2010.8.4.206

A Promoter SNP (rs1800682, -670C/T) of FAS Is Associated with Stroke in a Korean Population  

Kang, Sung-Wook (Kohwang Medical Research Institute, School of Medicine, Kyung Hee University)
Chung, Joo-Ho (Kohwang Medical Research Institute, School of Medicine, Kyung Hee University)
Kim, Dong-Hwan (Department of Physical Medicine & Rehabilitation, School of Medicine, Kyung Hee University)
Yun, Dong-Hwan (Department of Physical Medicine & Rehabilitation, School of Medicine, Kyung Hee University)
Yoo, Seung-Don (Department of Physical Medicine & Rehabilitation, School of Medicine, Kyung Hee University)
Kim, Hee-Sang (Department of Physical Medicine & Rehabilitation, School of Medicine, Kyung Hee University)
Seo, Wan (Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University)
Yoon, Jee-Sang (Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University)
Baik, Hyung-Hwan (Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University)
Publication Information
Genomics & Informatics / v.8, no.4, 2010 , pp. 206-211 More about this Journal
Abstract
The Fas (TNF receptor superfamily, member 6) (FAS)/FAS ligand (FASLG) interaction plays a central role in the regulation of programmed cell death. FAS and FASLG polymorphisms in promoter regions affect transcriptional activities. To investigate whether FAS and FASLG polymorphisms are associated with the development and clinical phenotypes of stroke, 2 promoter single nucleotide polymorphisms (SNPs) in FAS (rs1800682, -670C/T) and FASLG (rs763110, -844C/T) were selected and genotyped by direct sequencing in 220 stroke patients [107 ischemic stroke (IS), 77 intracerebral hemorrhage (ICH), and 36 subarachnoid hemorrhage (SAH)] and 369 control subjects. For the analysis of clinical symptoms, all stroke patients were divided into 3 clinical phenotypes according to the respective results of the National Institutes of Health Stroke Survey (NIHSS) and the Modified Barthel Index (MBI) and the presence or absence of complex regional pain syndrome (CRPS). The SNPStats, SNPAnalyzer, and Helixtree programs were used to analyze the genetic data. Multiple logistic regression models (codominant, dominant, and recessive) were used to estimate odds ratios (ORs), 95% confidence intervals (CIs), and p-values. The promoter SNP rs1800682 was associated with stroke in the codominant (OR=0.48, 95% CI=0.25-0.94, p=0.04) and dominant models (OR=0.51, 95% CI=0.30-0.87, p=0.011). However, a FASLG SNP (rs763110) was not in Hardy-Weinberg equilibrium (p<0.05). In the analysis of stroke types, rs1800682 was associated with IS in the codominant (OR=0.30, 95% CI=0.12-0.74, p=0.025), dominant (OR=0.44, 95% CI=0.23-0.88, p=0.018), and recessive models (OR=0.45, 95% CI=0.21-0.99, p=0.042). The genotype frequencies of rs1800682 were different between ICH and controls in the dominant model (OR=0.49, 95% CI=0.26-0.94, p=0.031) but not between SAH and controls. In the analysis of clinical symptoms, however, rs1800682 was not related to the 3 clinical phenotypes (NIHSS, MBI, and CRPS). These results suggest that a promoter SNP (rs1800682, -670C/T) in FAS may be associated with the development of stroke in the Korean population.
Keywords
FAS; FASLG; promoter; single nucleotide polymorphism; stroke;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Munshi, A., Rajeshwar, K., Kaul, S., Al-Hazzani, A., Alshatwi, A.A., Sai, Babu, M., Usha, A., and Jyothy, A. (2010). Interleukin-10-1082 promoter polymorphism and ischemic stroke risk in a South Indian population. Cytokine 52, 221-224.   DOI
2 Munshi, A., Sharma, V., Kaul, S., Rajeshwar, K., Babu, M.S., Shafi, G., Anila, A.N., Balakrishna, N., Alladi, S., and Jyothy, A. (2010). Association of the -344C/T aldosterone synthase (CYP11B2) gene variant with hyper-tension and stroke. J. Neurol. Sci. 296, 34-38.   DOI
3 Petrea, R.E., Beiser, A.S., Seshadri, S., Kelly-Hayes, M., Kase, C.S., and Wolf, P.A. (2009). Gender differences in stroke incidence and poststroke disability in the Framingham heart study. Stroke 40, 1032-1037.   DOI
4 Reich, A., Spering, C., and Schulz, J.B. (2008). Death receptor Fas (CD95) signaling in the central nervous system: tuning neuroplasticity? Trends Neurosci. 31, 478-486.   DOI
5 Reuter, B., Bugert, P., Stroick, M., Bukow, S., Griebe, M., Hennerici, M.G., and Fatar, M. (2009). TIMP-2 gene polymorphism is associated with intracerebral hemorrhage. Cerebrovasc. Dis. 28, 558-563.   DOI
6 Seo, J.C., Han, S.W., Yin, C.S., Koh, H.K., Kim, C.H., Kim, E.H., Leem, K.H., Lee, H.S., Park, H.J., Kim, S.A., Choe, B.K., Lee, H.J., Yim, S.V., Kim, C.J., and Chung, J.H. (2002). Evaluation of a Apo-1/Fas promoter polymorphism in Korean stroke patients. Exp. Mol. Med. 34, 294-298.   DOI   ScienceOn
7 Shi, K.L., He, B., Wang, J.J., and Zou, L.P. (2009). Role of TNF-alpha gene variation in idiopathic childhood ischemic stroke: a case-control study. J. Child Neurol. 24, 25-29.   DOI
8 Sugawara, T., Fujimura, M., Noshita, N., Kim, G.W., Saito, A., Hayashi, T., Narasimhan, P., Maier, C.M., and Chan, P.H. (2004). Neuronal death/survival signaling pathways in cerebral ischemia. NeuroRx. 1, 17-25.   DOI
9 Zhang, N., Yu, J.T., Yu, N.N., Lu, R.C., Ma, T., Wang, N.D., Miao, D., Song, J.H., and Tan, L. (2010). Interleukin-18 promoter polymorphisms and risk of ischemic stroke. Brain Res. Bull. 81, 590-594.   DOI
10 Zhu, Q., Wang, T., Ren, J., Hu, K., Liu, W., and Wu, G. (2010). FAS-670A/G polymorphism: A biomarker for the metastasis of nasopharyngeal carcinoma in a Chinese population. Clin. Chim. Acta. 411, 179-183.   DOI
11 Hanasaki, H., Takemura, Y., Fukuo, K., Ohishi, M., Onishi, M., Yasuda, O., Katsuya, T., Awata, N., Kato, N., Ogihara, T., and Rakugi, H. (2009). Fas promoter region gene polymorphism is associated with an increased risk for myocardial infarction. Hypertens. Res. 32, 261-264.   DOI
12 Hueber, A.O. (2000). CD95: more than just a death factor? Nat. Cell Biol. 2, E23-25.   DOI
13 Ikram, M.A., Seshadri, S., Bis, J.C., Fornage, M., DeStefano, A.L., Aulchenko, Y.S., Debette, S., Lumley, T., Folsom, A.R., van den Herik, E.G., Bos, M.J., Beiser, A., Cushman, M., Launer, L.J., Shahar, E., Struchalin, M., Du, Y., Glazer, N.L., Rosamond, W.D., Rivadeneira, F., Kelly-Hayes, M., Lopez, O.L., Coresh, J., Hofman, A., DeCarli, C., Heckbert, S.R., Koudstaal, P.J., Yang, Q., Smith, N.L., Kase, C.S., Rice K., Haritunians, T., Roks,G., de Kort, P.L., Taylor, K.D., de Lau, L.M., Oostra, B.A., Uitterlinden, A.G., Rotter, J.I., Boerwinkle, E., Psaty, B.M., Mosley, T.H., van Duijn, C.M., Breteler, M.M., Longstreth,W.T. Jr., and Wolf, P.A. (2009). Genomewide association studies of stroke. N. Engl. J. Med. 360, 1718-1728.   DOI
14 Kim, N.S., Ko, M.M., Cha, M.H., Oh, S.M., and Bang, O.S. (2010). Age and sex dependent genetic effects of neuropeptide Y promoter polymorphism on susceptibility to ischemic stroke in Koreans. Clin. Chim. Acta. 411, 1243-1247.   DOI
15 Matarin, M., Brown, W.M., Scholz, S., Simon-Sanchez, J., Fung, H.C., Hernandez, D., Gibbs, J.R., De Vrieze, F.W., Crews, C., Britton, A., Langefeld, C.D., Brott, T.G., Brown, R.D. Jr., Worrall, B.B., Frankel, M., Silliman, S., Case, L.D., Singleton, A., Hardy, J.A., Rich, S.S., and Meschia, J.F. (2007). A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release. Lancet Neurol. 6, 414-420.   DOI
16 Lanktree, M.B., Dichgans, M., and Hegele, R.A. (2010). Advances in genomic analysis of stroke: what have we learned and where are we headed? Stroke 41, 825-382.   DOI
17 Liu, Y., Wen, Q.J., Yin, Y., Lu, X.T., Pu, S.H., Tian, H.P., Lou, Y.F., Tang, Y.N., Jiang, X., Lu, G.S., and Zhang, J. (2009). FASLG polymorphism is associated with cancer risk. Eur. J. Cancer 45, 2574-2578.   DOI
18 Love, S. (2003). Apoptosis and brain ischaemia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 267-282.   DOI   ScienceOn
19 Broen, J., Gourh, P., Rueda, B., Coenen, M., Mayes, M., Martin, J., Arnett, F.C., Radstake, T.R., and European Consortium on Systemic Sclerosis Genetics. (2009). The FAS -670A>G polymorphism influences susceptibility to systemic sclerosis phenotypes. Arthritis. Rheum. 60, 3815-3820.   DOI
20 Broughton, B.R., Reutens, D.C., and Sobey, C.G. (2009). Apoptotic mechanisms after cerebral ischemia. Stroke 40, e331-339.   DOI   ScienceOn
21 Ethell, D.W., and Buhler, L.A. (2003). Fas ligand-mediated apoptosis in degenerative disorders of the brain. J. Clin. Immunol. 23, 363-370.   DOI
22 Cao, Y., Miao, X.P., Huang, M.Y., Deng, L., Lin, D.X., Zeng, Y.X., and Shao, J.Y. (2010). Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol. Carcinog. 49, 944-950.   DOI
23 Desbarats, J., Birge, R.B., Mimouni-Rongy, M., Weinstein, D.E., Palerme, J.S., and Newell, M.K. (2003). Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat. Cell Biol. 5, 118-125.   DOI
24 Doyle, K.P., Simon, R.P., and Stenzel-Poore, M.P. (2008). Mechanisms of ischemic brain damage. Neuropharmacology 55, 310-318.   DOI
25 Gil-Nunez, A. (2007). The metabolic syndrome and cerebrovascular disease: suspicion and evidence. Cerebrovasc. Dis. 24 Suppl 1, 64-75.   DOI
26 Grysiewicz, R.A., Thomas, K., and Pandey, D.K. (2008). Epidemiology of ischemic and hemorrhagic stroke: incidence, prevalence, mortality, and risk factors. Neurol. Clin. 26, 871-895.   DOI